Cargando…
Addressing the unmet needs of patients with BRAF-mutated melanoma in Latin America: Expert perspective
Melanoma represents an increasing public health burden with extensive unmet needs in Latin America (LA). A mutation in the BRAF gene is present in approximately 50% of all melanomas in White populations and is a target of precision medicine, with the potential to dramatically improve patient outcome...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043339/ https://www.ncbi.nlm.nih.gov/pubmed/36998456 http://dx.doi.org/10.3389/fonc.2023.1032300 |
_version_ | 1784913124658249728 |
---|---|
author | Salman, Pamela de Melo, Andreia Cristina Rico-Restrepo, Mariana Rodriguez, Jeronimo Russi, Andrea Schmerling, Rafael Aron Zambrano, Angela Cinat, Gabriela |
author_facet | Salman, Pamela de Melo, Andreia Cristina Rico-Restrepo, Mariana Rodriguez, Jeronimo Russi, Andrea Schmerling, Rafael Aron Zambrano, Angela Cinat, Gabriela |
author_sort | Salman, Pamela |
collection | PubMed |
description | Melanoma represents an increasing public health burden with extensive unmet needs in Latin America (LA). A mutation in the BRAF gene is present in approximately 50% of all melanomas in White populations and is a target of precision medicine, with the potential to dramatically improve patient outcomes. Thus, increased access to BRAF testing and therapy is LA must be explored. At a multi-day conference, a panel of Latin American experts in oncology and dermatology were provided with questions to address the barriers limiting access to testing for BRAF mutation in patients with melanoma in LA, who may be eligible for targeted therapy to improve their prognosis. During the conference, responses were discussed and edited until a consensus on addressing the barriers was achieved. Identified challenges included ignorance of BRAF-status implications, limited human and infrastructural resources, affordability and reimbursement, fragmented care delivery, pitfalls in the sample journey, and lack of local data. Despite the clear benefits of targeted therapies for BRAF-mutated melanoma in other regions, there is no clear path to prepare LA for a sustainable personalized medicine approach to this disease. Due to melanoma’s time-sensitive nature, LA must aim to provide early access to BRAF testing and consider mutational status within treatment decision making. To this end, recommendations are provided and include establishing multidisciplinary teams and melanoma referral centers and improving access to diagnosis and treatment. |
format | Online Article Text |
id | pubmed-10043339 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100433392023-03-29 Addressing the unmet needs of patients with BRAF-mutated melanoma in Latin America: Expert perspective Salman, Pamela de Melo, Andreia Cristina Rico-Restrepo, Mariana Rodriguez, Jeronimo Russi, Andrea Schmerling, Rafael Aron Zambrano, Angela Cinat, Gabriela Front Oncol Oncology Melanoma represents an increasing public health burden with extensive unmet needs in Latin America (LA). A mutation in the BRAF gene is present in approximately 50% of all melanomas in White populations and is a target of precision medicine, with the potential to dramatically improve patient outcomes. Thus, increased access to BRAF testing and therapy is LA must be explored. At a multi-day conference, a panel of Latin American experts in oncology and dermatology were provided with questions to address the barriers limiting access to testing for BRAF mutation in patients with melanoma in LA, who may be eligible for targeted therapy to improve their prognosis. During the conference, responses were discussed and edited until a consensus on addressing the barriers was achieved. Identified challenges included ignorance of BRAF-status implications, limited human and infrastructural resources, affordability and reimbursement, fragmented care delivery, pitfalls in the sample journey, and lack of local data. Despite the clear benefits of targeted therapies for BRAF-mutated melanoma in other regions, there is no clear path to prepare LA for a sustainable personalized medicine approach to this disease. Due to melanoma’s time-sensitive nature, LA must aim to provide early access to BRAF testing and consider mutational status within treatment decision making. To this end, recommendations are provided and include establishing multidisciplinary teams and melanoma referral centers and improving access to diagnosis and treatment. Frontiers Media S.A. 2023-03-14 /pmc/articles/PMC10043339/ /pubmed/36998456 http://dx.doi.org/10.3389/fonc.2023.1032300 Text en Copyright © 2023 Salman, de Melo, Rico-Restrepo, Rodriguez, Russi, Schmerling, Zambrano and Cinat https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Salman, Pamela de Melo, Andreia Cristina Rico-Restrepo, Mariana Rodriguez, Jeronimo Russi, Andrea Schmerling, Rafael Aron Zambrano, Angela Cinat, Gabriela Addressing the unmet needs of patients with BRAF-mutated melanoma in Latin America: Expert perspective |
title | Addressing the unmet needs of patients with BRAF-mutated melanoma in Latin America: Expert perspective |
title_full | Addressing the unmet needs of patients with BRAF-mutated melanoma in Latin America: Expert perspective |
title_fullStr | Addressing the unmet needs of patients with BRAF-mutated melanoma in Latin America: Expert perspective |
title_full_unstemmed | Addressing the unmet needs of patients with BRAF-mutated melanoma in Latin America: Expert perspective |
title_short | Addressing the unmet needs of patients with BRAF-mutated melanoma in Latin America: Expert perspective |
title_sort | addressing the unmet needs of patients with braf-mutated melanoma in latin america: expert perspective |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043339/ https://www.ncbi.nlm.nih.gov/pubmed/36998456 http://dx.doi.org/10.3389/fonc.2023.1032300 |
work_keys_str_mv | AT salmanpamela addressingtheunmetneedsofpatientswithbrafmutatedmelanomainlatinamericaexpertperspective AT demeloandreiacristina addressingtheunmetneedsofpatientswithbrafmutatedmelanomainlatinamericaexpertperspective AT ricorestrepomariana addressingtheunmetneedsofpatientswithbrafmutatedmelanomainlatinamericaexpertperspective AT rodriguezjeronimo addressingtheunmetneedsofpatientswithbrafmutatedmelanomainlatinamericaexpertperspective AT russiandrea addressingtheunmetneedsofpatientswithbrafmutatedmelanomainlatinamericaexpertperspective AT schmerlingrafaelaron addressingtheunmetneedsofpatientswithbrafmutatedmelanomainlatinamericaexpertperspective AT zambranoangela addressingtheunmetneedsofpatientswithbrafmutatedmelanomainlatinamericaexpertperspective AT cinatgabriela addressingtheunmetneedsofpatientswithbrafmutatedmelanomainlatinamericaexpertperspective |